Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.

•Atezolizumab provided durable survival benefit across all best-response subgroups.•Atezolizumab long-term survivors (LTSs) were enriched for high programmed death-ligand 1 (PD-L1) expression.•Atezolizumab LTSs also included patients with PD-L1–negative tumours.•Atezolizumab LTSs included patients with progressive disease as best response.•Extended atezolizumab exposure showed tolerable safety in LTS.